On December 24, 2024, David Campbell, President and Chief Executive Officer of Janux Therapeutics Inc, sold 25,000 shares of the company. Following this transaction, the insider now owns 217,054 shares of Janux Therapeutics Inc. The details of this transaction can be found in the SEC Filing.
Janux Therapeutics Inc (JANX, Financial) is a biotechnology company focused on developing innovative therapies for cancer treatment. The company utilizes its proprietary technology to engineer T cell engager immunotherapies designed to target and eliminate cancer cells while sparing healthy tissue.
Over the past year, David Campbell has sold a total of 115,000 shares and has not purchased any shares. The insider transaction history for Janux Therapeutics Inc indicates that there have been 1 insider buy and 15 insider sells over the same period.
On the day of the recent sale, shares of Janux Therapeutics Inc were trading at $56.19, giving the stock a market cap of $3.172 billion. The stock's GF Value is estimated at $21.29, resulting in a price-to-GF-Value ratio of 2.64. This suggests that the stock is significantly overvalued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also incorporates a GuruFocus adjustment factor based on the company’s past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
